EDDA Technology receives FDA clearance for IQQA-Guide system for surgical procedures

EDDA Technology, a global leading provider in advanced imaging-guided precision treatment solutions, announced today that the company has received FDA clearance on IQQA^®-Guide, a system that supports intra-operative precision 3D navigation for surgical procedures of thoracic, abdominal, and pelvic soft-organs.

IQQA^®-Guide is the latest addition to the IQQA^® Platform and Product Suite. It expands the award-winning IQQA^® precision 3D imaging analytics into the operating room. Fully quantified and patient-specific IQQA^® anatomic models are extracted from multi-modality images, and utilized for on-the-fly 3D navigation to support physicians in "seeing through" organ surfaces and quantitatively referencing anatomies of interest in 3D during surgery. Clinical studies (WICO 2015) suggest that IQQA^®-Guide may help reduce the use of intra-operative CT scans during imaging-guided surgical procedures.

The treatment planning and follow-up assessment features provided by IQQA^® -BodyImaging, a part of the IQQA^® Platform, have already been widely used for liver, kidney, and lung cancers. IQQA^® -BodyImaging has been proven to provide significant time-saving and improved patient care in more than 22,000 cases.

"With the latest FDA clearance, the IQQA^® Platform now covers pre-operative planning, intra-operative navigation and monitoring, and post-operative assessment to complete the full cycle of imaging-guided precision treatment," said Dr. Jianzhong Qian, President and CEO of EDDA Technology. "Powered by our precision 3D capabilities, IQQA^®-Guide may help facilitate the next generation of minimally invasive and robotic treatments in precision medicine".

EDDA will exhibit its IQQA^® Platform and Product Suite as well as cloud-based service in Booth #8127 at RSNA 2015.

SOURCE EDDA Technology, Inc.